Veritas In Silico Inc. (JP:130A) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veritas In Silico Inc. (VIS) has signed a memorandum of understanding with Mitsubishi Gas Chemical (MGC) to jointly research, develop, and manufacture innovative RNA-targeted drugs. Utilizing VIS’s ibVIS® discovery platform and MGC’s expertise in GMP manufacturing, the partnership aims to create high-quality nucleic acid medicines. This collaboration, however, is not expected to affect VIS’s financial forecasts for the fiscal year ending December 2024.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.